Search
To compare the developmental and behavioral outcomes of children experiencing an initial vaccine-proximate (VP) febrile seizure (FS) to those having a non-VP-FS (NVP-FS) and controls who have not had a seizure.
A multi-country randomized, placebo-controlled trial of the safety, immunogenicity and efficacy of respiratory syncytial virus (RSV) F-protein nanoparticle vaccine was undertaken in 4,636 pregnant women and their infants. RSV F-protein vaccine was safe and immunogenic in the pregnant women inducing anti-F IgG, palivizumab-competing antibodies and RSV neutralizing antibodies that were transferred to the fetus.
Respiratory syncytial virus (RSV) is a global cause of severe respiratory morbidity and mortality in infants. While preventive and therapeutic interventions are being developed, including antivirals, vaccines and monoclonal antibodies, little is known about the global molecular epidemiology of RSV. INFORM is a prospective, multicenter, global clinical study performed by ReSViNET to investigate the worldwide molecular diversity of RSV isolates collected from children less than 5 years of age.
Eight outstanding researchers from The Kids Research Institute Australia and the Institute-led Broome STEM Festival are finalists in the 2025 Premier’s Science Awards.
Free Family-Friendly Science Fun During National Science Week 2025. Get ready for an awesome adventure into the world of Science, Technology, Engineering and Mathematics!
We honour the memory of Emeritus Professor Michael Alpers, a colleague and friend to many at The Kids Research Institute Australia, who passed away on December 3, 2024.
Vital research promoting sun smart choices and skin cancer prevention for young Aboriginal people is now underway at The Kids Research Institute Australia thanks to a $100,000 Perpetual 2024 IMPACT Philanthropy grant.
A team led by Dr Joseph Kado from the Wesfarmers Centre of Vaccines and Infectious Diseases, based at The Kids Research Institute Australia, and The University of Western Australia (UWA) has been awarded $5 million by the Federal Government in a major push to prevent rheumatic heart disease across the Pacific.
The urgency for a world-first respiratory syncytial virus vaccine is at an all-time high.
A rapid test to detect antibiotic-resistant skin infections in Aboriginal children could be a step closer, thanks to support from the FHRIF.